Advances in the management of constipation-predominant irritable bowel syndrome

The role of linaclotide

Siegfried W.B. Yu, Satish Sanku Chander Rao

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1–7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39–7.69, and at 26 weeks with a NNT of 4.93–5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.

Original languageEnglish (US)
Pages (from-to)193-205
Number of pages13
JournalTherapeutic Advances in Gastroenterology
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Irritable Bowel Syndrome
Constipation
Numbers Needed To Treat
United States Food and Drug Administration
Abdominal Pain
Diarrhea
Clinical Trials
linaclotide
Therapeutics

Keywords

  • IBS-C
  • constipation
  • irritable bowel syndrome
  • linaclotide

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Advances in the management of constipation-predominant irritable bowel syndrome : The role of linaclotide. / Yu, Siegfried W.B.; Rao, Satish Sanku Chander.

In: Therapeutic Advances in Gastroenterology, Vol. 7, No. 5, 01.01.2014, p. 193-205.

Research output: Contribution to journalReview article

@article{020948159cf44d58a94bcec412fd3ff1,
title = "Advances in the management of constipation-predominant irritable bowel syndrome: The role of linaclotide",
abstract = "Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1–7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39–7.69, and at 26 weeks with a NNT of 4.93–5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5{\%} of patients.",
keywords = "IBS-C, constipation, irritable bowel syndrome, linaclotide",
author = "Yu, {Siegfried W.B.} and Rao, {Satish Sanku Chander}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1756283X14537882",
language = "English (US)",
volume = "7",
pages = "193--205",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Advances in the management of constipation-predominant irritable bowel syndrome

T2 - The role of linaclotide

AU - Yu, Siegfried W.B.

AU - Rao, Satish Sanku Chander

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1–7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39–7.69, and at 26 weeks with a NNT of 4.93–5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.

AB - Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1–7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39–7.69, and at 26 weeks with a NNT of 4.93–5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.

KW - IBS-C

KW - constipation

KW - irritable bowel syndrome

KW - linaclotide

UR - http://www.scopus.com/inward/record.url?scp=84904744161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904744161&partnerID=8YFLogxK

U2 - 10.1177/1756283X14537882

DO - 10.1177/1756283X14537882

M3 - Review article

VL - 7

SP - 193

EP - 205

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 5

ER -